Growth opportunities Neos Therapeutics is a mid-sized pharmaceutical player focused on extended-release ADHD therapies with a history of product launches and potential for expansion in XR platforms. This suggests opportunities to partner on co-development, manufacturing capacity scaling, or distribution arrangements for additional XR formulations.

Strategic alliance potential Past licensing and merger activity with Aytu indicates openness to strategic partnerships and acquisitions. BD teams should explore distribution, co-promotion, or technology licensing for Neos XR delivery platforms in ADHD and potential adjacent CNS indications.

Manufacturing capability Neos emphasizes proprietary modified-release drug delivery platforms and in-house manufacturing. This positions them as a potential contract manufacturing partner for specialty XR formulations or for scaling up supply to meet growing ADHD treatment demand.

Market momentum Historical rapid launch of Adzenys ER and other XR ADHD products signals a track record of nimble commercial execution. Opportunity to propose streamlined market access initiatives, patient support programs, and payer strategies to accelerate new product adoption.

Financial readiness With funding of around $204M and revenue in the tens of millions, Neos may be prioritizing growth initiatives and partnerships to maximize ROI. This suggests urgency for value-focused proposals, strategic collaborations, and clear ROI models for potential deals.